Kevin Koch - 12 Aug 2025 Form 4 Insider Report for Edgewise Therapeutics, Inc. (EWTX)

Role
President and CEO, Director
Signature
/s/John R. Moore Attorney-in-Fact for Kevin Koch
Issuer symbol
EWTX
Transactions as of
12 Aug 2025
Net transactions value
-$106,764
Form type
4
Filing time
14 Aug 2025, 19:42:14 UTC
Previous filing
07 May 2025
SEC
View on sec.gov

Reporting Owners (1)

Name Relationship Address Signature Signature date CIK
KOCH KEVIN President and CEO, Director C/O EDGEWISE THERAPEUTICS, INC., 1715 38TH STREET, BOULDER /s/John R. Moore Attorney-in-Fact for Kevin Koch 14 Aug 2025 0001185829

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
transaction EWTX Common Stock Options Exercise $0 +17,968 +87% $0.000000 38,587 12 Aug 2025 Direct
transaction EWTX Common Stock Sale $106,764 -7,972 -21% $13.39 30,615 12 Aug 2025 Direct F1, F2
holding EWTX Common Stock 259,554 12 Aug 2025 KTK Family Enterprise, LLC
holding EWTX Common Stock 26,410 12 Aug 2025 Adrienne R. Koch Heritage Trust
holding EWTX Common Stock 26,410 12 Aug 2025 Matthew K. Koch Heritage Trust
holding EWTX Common Stock 26,410 12 Aug 2025 Nicole M. Soldow Heritage Trust

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
transaction EWTX Restricted Stock Units Options Exercise $0 -17,968 -25% $0.000000 53,907 12 Aug 2025 Common Stock 17,968 $0.000000 Direct F3
transaction EWTX Restricted Stock Units Award $0 +87,500 $0.000000 87,500 12 Aug 2025 Common Stock 87,500 $0.000000 Direct F4
transaction EWTX Stock Option (Right to Buy) Award $0 +525,000 $0.000000 525,000 12 Aug 2025 Common Stock 525,000 $13.39 Direct F5
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 Represents the number of shares sold to cover the statutory tax withholding obligations in connection with the vesting of Restricted Stock Units (RSUs). This sale satisfies the minimum statutory tax withholding obligations to be funded by a "sell-to-cover" transaction and does not represent a discretionary sale by the Reporting Person
F2 The price reported in column 4 is an average price. These shares were sold in multiple transactions at prices ranging from $13.36 to $13.49, inclusive. The Reporting Person undertakes to provide the Issuer, any security holder of the Issuer or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.
F3 Restricted Stock Units ("RSUs") granted to the reporting person for no additional cash consideration, each of which represent a contingent right to receive one share of Edgewise Therapeutics, Inc. common stock upon the vesting of these RSUs in four equal annual installments beginning on August 12, 2025.
F4 Restricted Stock Units ("RSUs") granted to the reporting person for no additional cash consideration, each of which represent a contingent right to receive one share of Edgewise Therapeutics, Inc. common stock upon the vesting of these RSUs in four equal annual installments beginning on August 12, 2026.
F5 1/48th of the shares subject to the option vest each month beginning on September 12, 2025, subject to the Reporting Person continuing as a service provider through each vest date.

Remarks:

In previous Forms 4, a duplicate 26,410 shares held indirectly were reported in error.